FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.
What happened
FDA reviewed the company's website (last visited October 2026) rather than doing an inspection. The site sells umbilical cord derived and exosome products as IV treatments and combination packages, with claims about joint pain, inflammation, tissue repair, immune and hormonal support, and skin aging. FDA said those claims make the products drugs and biological products that need an approved application or license, and that the umbilical cord product does not qualify for the lighter tissue-bank route.
What FDA found
The products are new drugs sold without an FDA-approved application.
Section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)The products are biological products sold without a biologics license.
Section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1)The website claims the products treat or affect the body, which makes them drugs.
Section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1)The umbilical cord product is not intended for homologous use, meaning it is not meant to do the same basic job in the patient that umbilical cord does in the donor.
21 CFR 1271.3(c) and 21 CFR 1271.10(a)(2)Because that criterion is not met, the product is not regulated only as a tissue under section 361 and needs premarket review.
21 CFR 1271.10(a)Shipping the products across state lines without an approved application is prohibited.
Section 301(d) of the FD&C Act, 21 U.S.C. § 331(d)
What FDA wants
FDA asks the company to write back within 15 working days describing the steps it has taken or will take to fix the violations and prevent them from recurring, with supporting documents. If the company disagrees that it is in violation, it should send its reasoning and evidence.
Who should pay attention
- IV hydration and concierge clinics selling stem cell or exosome IVs
- medical directors who sign off on regenerative therapy menus
- suppliers and marketers of umbilical cord or exosome products
This is a summary. Read the original letter on fda.gov.